Phase 0 Trial Evaluating the Effect of Temsirolimus on Known Pharmacodynamic Targets
Phase 0 Trial Evaluating the Effect of Temsirolimus on Known Pharmacodynamic Targets is a EARLY_PHASE1 clinical asset sponsored by M.D. Anderson Cancer Center in Advanced Cancer. SEO and diligence focus: Temsirolimus, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: Advanced Cancer
Modality: small molecule
Target: Temsirolimus
Sponsor: M.D. Anderson Cancer Center
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 22, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Temsirolimus
View original source fields
Condition raw: Advanced Cancer
Condition normalized: Advanced Cancer
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Temsirolimus
Target normalized: Temsirolimus